The present study assesses the possible involvement of the renin-angiotensin system (RAS) and the sympathetic nervous system (SNS) in thyroxine-induced cardiac hypertrophy.
Introduction
Changes in hemodynamic loading appear to be an important stimulus for cardiac growth. However, dissociation between elevated arterial pressure and increased myocardial mass has been demonstrated in hypertensive cardiac hypertrophy in animals and humans (25) . This dissociation suggests that, in addition to blood pressure, various stimuli are involved in the development and regression of cardiac hypertrophy (25) . During the past several decades, many neural and hormonal stimuli have been implicated in cardiac muscle growth, including, but not limited to, α-and β-adrenergic agonists, angiotensin II, glucocorticoids, insulin, growth hormone, glucagon and thyroxine (T4) (25) .
Mechanisms of cardiac hypertrophy produced by elevated T4 include a direct effect of the hormone on the heart, and indirect effects related to stimulation of the adrenergic nervous system, or altered left-ventricular loading conditions. Decreased systemic vascular resistance and the subsequent increase in cardiac work contribute to this thyroxine-induced hypertrophy (15, 25) . However, in support of a direct effect of thyroid hormone on heart growth, some authors have observed that thyroxine-induced cardiac hypertrophy in isolated heart preparations is accompanied by increased (31) quantity and rate of protein and ribosome synthesis (33) .
It is well established that the enhanced hemodynamic parameters produced by increased sympathetic nervous system (SNS) activity constitute an important factor in the cardiac hypertrophy induced by hyperthyroidism (16) . Moreover, chronic administration of the β-agonist isoproterenol also increases cardiac weight (20, 40) . Thus, many of the clinical symptoms findings of hyperthyroidism as increased heart rate, cardiac output and enhanced myocardial contractility are frequent and have led to the conclusion that hyperthyroidism is a hyperadrenergic state (22) . However, there are conflicting reports regarding the preventative nature of sympathetic inhibition in hyperthyroidism-associated cardiac hypertrophy (11, 15) .
In addition to the clear influences of the SNS, the renin-angiotensin system (RAS) may contribute to the cardiovascular modifications observed in hyperthyroidism. For example, RAS inhibitors are beneficial in the treatment of chronic heart failure and acute myocardial ischemia, as well as in regression of cardiac hypertrophy (9) . Recently, Kobori et al. (17) reported that the local RAS plays a primary role in the development of hyperthyroidism-induced cardiac hypertrophy. These authors demonstrated that thyroid hormone activates the circulating and tissue RAS without involving the SNS. This may account for the cardiac hypertrophy observed in hyperthyroidism (18) . Under these conditions, thyroid hormone directly stimulates renin mRNA in vivo (18) , in vitro (13) and increase both the synthesis and secretion of angiotensinogen and angiotensin II receptors (32) . Conversely, thyroidectomy-induced (10) and methimazole-induced (25) thyroid dysfunction decrease plasma renin activity. These findings suggest that hyperthyroidisminduced cardiac hypertrophy could be involved in changes in circulating RAS or SNS activity.
The present study was designed to address the role of β-adrenergic versus that of the cardiac renin-angiotensin system in thyroxine-induced cardiac hypertrophy. Two objectives were set. The first objective was to assess effects of two different dose levels (25 and 100µg/100g BW) of thyroxine, for 7 days, on cardiac hypertrophy development. The second objective was to compare the effects of treatment with an ACE inhibitor or AT1-receptor blocker versus those of a β-adrenergic blocker on thyroxine-induced cardiac hypertrophy. The β-adrenergic blockade in hyperthyroidism has been previously analyzed in short-term (40) and long-term experiments (12) . However, the effects of drugs known to block RAS and prevent cardiomyocyte remodeling in other models of hypertrophy (6) have not yet been well established in thyroid hormone-induced cardiac hypertrophy.
Materials and Methods

Animals
Care and use of laboratory animals were according to NIH guidelines. Male Wistar rats weighing 170-250g were obtained from the Instituto de Ciências Biomédicas. They received a rat pellet diet and water ad libitum until the time of the experiment and were maintained in a temperature and light-controlled (24°C; 12h-on/12h-off) environment. The L-thyroxine (T4) was purchased from the Sigma Chemical Company (St. Louis, USA).
Initially, rats were randomized into four groups: hypothyroid (Hypo), hyperthyroid (T4-25 and T4-100) and control. In the Hypo group, the rats were surgically thyroidectomized and treated with methimazole (0.05%) added to their drinking water for 7 days.
Hyperthyroidism was induced in T4-25 and T4-100 rats by daily intraperitoneal injections of T4 (25 and 100 µg ·100g -1 BW · day -1 , respectively) for 7 days. The hyperthyroid group T4-100 was then subdivided into four groups: T4-100, T4+enalapril (T4-ENA), T4+losartan (T4-LOS) and T4+propanolol (T4-PROP). Enalapril, losartan and propanolol were administrated in the drinking water once a day for 7 days at doses of 250mg/L (19), 200mg/L (29) and 750mg/L (15), respectively, during treatment. All rats were sacrificed 24h after the last dose of T4.
Hemodynamic parameters
In all rats, systolic blood pressure (SBP) and heart rate (HR) were measured daily at approximately the same time of day by tail-cuff plethysmograph (Kent Scientific Corp).
Additionally, body weight (BW) was measured daily and SBP and weight were last determined immediately preceding sacrifice. Rats were familiarized with the apparatus for a total of 7 days prior to measurements being taken.
Heart Preparation
Morphological data were obtained using a previously reported method (35) . After one week, animals were anesthetized with sodium pentobarbital (45 mg/kg, intraperitoneally) and the thorax was opened. Cardiac arrest was induced by injection of potassium chloride (14 mM). The heart was then quickly removed, blotted, and weighed.
The ventricles were carefully dissected, weighed, fixed in 10% neutral formalin and prepared for microscopic analysis (as described below).
Measurement of cardiac hypertrophy
Cardiac hypertrophy was assessed by the measurement of wet heart weight (HW) in milligrams and the ratio of HW in milligrams to animal BW in grams; HW/BW in mg/g. Cardiac hypertrophy was confirmed by analyzing HW as dry weight (data not shown).
Microscopic studies
The left ventricle was transversely sectioned at midportion between apex and base.
A cross-sectional slice was removed, fixed in 10 % neutral formalin, at room temperature for 48-72 h. The slice was dehydrated in an increasing alcohol series, immersed in benzene for 20 min, and embedded in paraffin. The samples were sectioned at 5µm and 12 nonconsecutive sections were collected and stained with Hematoxylin-eosin for morphometric analysis. To identify possible interstitial fibrosis, sections (10 µm in thickness) from Hypo and Hyper (T4-25 and T4-100) group were stained by Sirius-red method and examined under polarized light to identify collagen fibers (14) . A stereological method (number of points) was used to quantify collagen fibers in the myocardium of nine sections from 3 rats in each group according to Mandarim-De-Lacerda (24) . The left ventricular wall thickness and chamber size were evaluated in 5 rats from both the Hyper (T4-100) and control groups. The wall thickness was measured as the distance between the endocardium and epicardium on the lateral wall, disregarding the papillary muscles. The measurements were taken across a line perpendicular to the curvature of the ventricular wall, using the histological section presenting the least technical artifacts. The left ventricular chamber size was evaluated on the same histological section by measuring the cross-sectional area of the left ventricular lumen. The measurements were performed with a magnification of 25X, using a microscopic imageanalysis system (Zeiss, KS 300).
Statistical analysis
The data are shown as means ± SE. Statistical analysis was performed using ANOVA and P values < 0.05 were accepted as statistically significant. Tukey's post hoc test was used to make individual comparisons between groups when a significant change was observed with ANOVA. Correlation coefficients were calculated using linear regression analysis.
Results
Hemodynamic Parameters
The parameters of Systolic Blood Pressure (SBP) and Heart Rate (HR) after thyroxine administration, after thyroidectomy (hypothyroid group) and after treatment with diverse inhibitors are summarized in Table 1 
Cardiac Hypertrophy
The data referring to BW before and after treatment and HW are summarized in Table 2 . The BW at the beginning of the experiment was the same in all groups of rats.
However, BW gain during the 7-day-study period was not similar in hypothyroid rats and significantly different when they were sacrificed (191.1 ± 17.8 g in hypothyroid group vs.
224.6 ± 11.3 g in control). The T4-100 group presented a significant increase in HW (18%) compared to the control group (Table 2 ) and in both T4-treated groups (T4-25 and T4-100) a significant increase (P<0.001) in the HW/BW ratio was observed (19.5 % and 21.3 %, respectively) ( Table 3 ). In contrast, the HW/BW ratio was significantly decreased in hypothyroid rats (P<0.001). The hypertrophy induced by hormone in either ventricle was analyzed in some animals. Hypertrophy did not develop symmetrically; the percentage of weight gain in the left and the right ventricles was not equal. In fact, the weight gain of the right ventricle was more pronounced with both dose levels (+ 42.9 % for T4-25 and + 36.4
% for T4-100) compared to the left ventricle (+ 9.6 % for T4-25 and 17.3 % for T4-100). This is also reflected by an increase in the right-ventricle/left-ventricle (RV/LV) weight ratio (Table 3 ). In addition, the hearts of hyperthyroid rats (T4-100) showed an increase in the ratio of left ventricle wall thickness to left ventricle chamber size (mm/mm 2 ), which might suggest a concentric hypertrophy, however, this change was not significant (0.36 ± 0.12 vs. 0.43 ± 0.17 to control group, n=5).
Compared with the higher dose of T4 alone (T4-100 group), the use of enalapril and propanolol combined with T4 significantly reduced BW, HW and HW/BW ratio, indicating that these drugs were able to prevent thyroid hormone-induced cardiac hypertrophy (Table   2 ; Fig. 1 ). However, the combination of T4 and losartan did not affect either BW, HW (Table 2) , or the HW/BW ratio (Fig. 1) . These results were confirmed when the dry heart mass/body mass ratio was determined (data not shown).
Morphological data
Cardiomyocyte analysis:
Cardiac hypertrophy data from the different experimental groups were analyzed and also included measurements of transverse fiber diameter (myocyte width). Figure 1 shows the relation between cardiac hypertrophy expressed as HW/BW ratio and myocyte width.
At both dose levels (25 µg and 100 µg), the thyroid hormone promoted a significant increase in myocyte transverse diameter when compared with the control group (18.0 ± 1.36 and 17.9 ± 1.31 vs. 15.9 ± 1.6; P<0.05). Hypothyroidism tended to decrease the transverse myocyte diameter, although the difference was not statistically significant.
The administration of specific RAS inhibitors or an adrenergic response inhibitor induced a significant decrease (P<0.01) in transverse myocyte diameter in animals treated with T4. In comparison to the T4-100 group, transverse myocyte diameter was reduced by 18.4% in the enalapril group, 17.3% in the losartan group, and 14% in the propanolol group. However, there was no significant difference between the groups, neither was there any significant difference in relation to the control group. Therefore, the increase in myocyte diameter promoted by T4 was significantly inhibited by administration of these drugs. Figure 2 shows the relation between HW/BW ratio and average myocyte width and demonstrates a good correlation (r = 0.96) between these two parameters.
Interstitial connective tissue:
To evaluate whether thyroid hormone-induced cardiac hypertrophy was accompanied by cardiac fibrosis, we examined the presence of collagen fibers in the transverse sections of control, Hypo and L-thyroxin-treated hearts (Figure 3) . Under polarized light, the Sirius-red stained sections exhibited scarce yellow or green collagen fibers in the myocardial region. The collagen quantification showed that there was no significant difference between the groups, neither was there any significant difference in relation to the control group ( Figure 3 ).
Discussion
The major finding of this study is that specific RAS inhibitors or adrenergic Chronic hyperthyroidism has typically been associated with simultaneous increases in blood pressure (5). However, in this acute study, there was no difference in systolic blood pressure between T4-treated animals and control group animals, indicating that the cardiac hypertrophy was not due to elevated hemodynamic parameters. Although dissociation between elevated arterial pressure and increased myocardial mass has been observed in this acute model of cardiac hypertrophy, hypothyroid rats presented decreased SBP, HW, BW and HW/BW ratio. This demonstrates that basal levels of thyroid hormone are very important for cardiac tissue metabolism and development and for maintenance of hemodynamic parameters. Interestingly, despite the fact that the hypothyroid group exhibited a significant reduction in HW/BW ratio, transverse cardiomyocyte diameter decreased. However, it did not differ significantly in relation to that of the control group.
Although the basis for this discrepancy is not clear, it is possible, considering that cardiac tissue is constituted by other cell types besides cardiomyocytes, that the situations of absence or deficiency of thyroid hormone which occur in hypothyroidism might compromise the development and fibroblasts proliferation, thereby reducing cardiac mass.
According to Pernitsky & Anderson (28), triiodothyronine (T3) treatment induces
proliferation of fibroblasts in vitro. In addition, it is possible that a significant reduction in cardiomyocyte diameter occurs after a longer period of hormone absence. Considering that decreased ventricular filling normally accompanies this condition, it is also possible that the drop in HW/BW observed in hypothyroid rats is due to decreased cell length. Another significant finding of the present investigation is that, despite the increased ratio of HW to BW, this hypertrophy was not accompanied by marked cardiac fibrosis, evidenced by collagen being poorly identified in the Picrosirius-stained tissue sections. Yao & Eghbali (39) and Weber et al. (38) showed that, in contrast to what is usually seen in other models of hypertrophy, collagen deposition did not increase in the thyroxine-induced myocardial hypertrophy model. These authors observed that, while thyroid hormone promotes the proliferation capacity of cardiac fibroblasts, it specifically inhibits the expression of cytoskeletal protein and collagen type I genes and is not likely to induce cardiac fibroblast hypertrophy.
Hyperthyroidism and renin-angiotensin system
Several mechanisms of hyperthyroid-induced cardiac hypertrophy have been proposed. Recently, some investigators have suggested that the RAS plays an important role in the development of cardiac hypertrophy in hyperthyroid rats demonstrating an activated circulating RAS in hyperthyroidism (3, 18, 32) . In the present study, enalapril or losartan was administered to hyperthyroid rats in order to confirm whether the RAS is involved in this model of cardiac hypertrophy and to compare the effects of these drugs in this model.
Our data show that acute treatment with the angiotensin-converting enzyme (ACE)
inhibitor, enalapril, at a dose that did not decrease blood pressure, attenuated cardiac hypertrophy (as estimated by the ratio of HW to BW) in rats induced to hyperthyroidism. Several studies have focused on the effect of angiotensin receptor blockers (ARBs) on the development of pressure-overload hypertrophy. These drugs prevent in vivo left ventricle pressure-overload hypertrophy and reduce the stretch-induced hypertrophic response in cardiac myocytes (6) . In the present study, we also analyzed the effects of angiotensin II receptor blockade. Losartan was not able to prevent the increase in the HW/BW ratio of animals induced to hyperthyroidism. However, a significant decrease in the diameter of myocytes was observed in these animals. The reason for this discrepancy between HW/BW ratio and the morphometric analysis may be due to the varying distribution of AT1 receptors in the cardiac cells and consequently varying efficacy of losartan in prevention of cardiomyocyte hypertrophy in relation to growth of non-myocyte cells, principally fibroblasts. Treatment with an AT1 receptor antagonist was not able, in this study, to prevent the increase in the HW/BW ratio. However, Crawford et al. (8) demonstrated that angiotensin II, acting through the angiotensin type I (AT1) receptor, stimulates fibronectin and expression of collagen type I and IV in association with the proliferation of interstitial fibroblasts by direct action and that this could be prevented by losartan, an AT1 receptor antagonist. However, it was recently reported that neither losartan, an AT1 receptor blocker, nor quinapril, an angiotensin I-converting enzyme inhibitor, was able to prevent isoproterenol-induced cardiac hypertrophy (21) . Thus, the observed diversity of response in these models indicates that specific stimuli sometimes influence the onset and development of cardiac hypertrophy. Furthermore, data obtained in our laboratory show that a longer period of treatment (14 days) with T4-100 + LOS prevented the increase in the HW/BW ratio (T4-100: 3.76 ± 0.22, T4-LOS: 3.24 ± 0.22;
P<0.01; n = 7). Thus, it is possible that losartan acts differently on myocytes than on nonmyocyte cells, and that myocytes are more sensitive to the action of the drug than are other cells.
Since ACE and AT1 are on successive pathways in the RAS, the primary effect of these agents and the underlying mechanism were previously believed to be identical (34).
However, it has been reported that cardioprotection by ACE inhibitors includes different cascades from ANG II reduction or AT1 blockade, which implies that the pathways for preventing structural changes are different for ACE inhibitors than for AT1 antagonists (30) . Considering that ACE inhibitors inhibit the breakdown of bradykinin, which causes an increase in nitric oxide production independent of the regulation of ANG II production (34), ACE inhibitors may exert beneficial effects through a bradykinin-NO pathway.
Therefore, it is possible that the observed higher efficacy of enalapril treatment, compared with treatment with losartan, is due to the effects of bradykinin-dependent pathways.
Hyperthyroidism and adrenergic response
The role of the beta-adrenergic nervous system in the development of thyrotoxicosis is controversial. Hyperthyroidism has been found to be associated with increased cardiac β-receptor density (4). Moalic et al. (26) showed an increased expression of β1-adrenergic receptor mRNA in response to thyroxine administration However, this was associated with decreased expression in pressure overload-induced cardiac hypertrophy, suggesting that the adrenergic system could play a role in the development of cardiac hypertrophy in chronic hyperthyroidism. In our study of an acute hyperthyroidism model, propanolol was used to block the β-adrenergic system. Cardiac hypertrophy, as estimated by the HW/BW ratio and by cardiomyocyte width, decreased significantly in the propanolol-treated hyperthyroid hearts. These data are not in agreement with those of Cooper et al. (7) , who reported that adrenergic stimulation in cats is not necessary for thyroxine-induced hypertrophy. In addition, a morphologic study showed that propanolol does not alter the degree of myocyte hypertrophy in hyperthyroid rats, but modifies myocyte geometry, increasing cell length (12) . This discrepancy may be related to differences in the dosages of propanolol and thyroid hormone, differences in species or sex of animals or to duration of treatment. As Results are expressed as means ± SD; numbers in parentheses, no. of animals used to obtain HW/BW ratio/myocyte width. Hatched bars = HW/BW, solid bars = myocyte width. 
